RUI-products
Official Sponsor
V, also known as Viagra or Sildenafil Citrate, was the first PDE5 Inhibitor made available for our research. The primary use of V in our research is in the treatment of erectile dysfunction in research subjects. Interestingly enough the compound is observed in research to exhibit a profound effect in erectile response regardless of the presence of erectile dysfunction or not.
Initially this research compound was designed for the research of hypertension, or high blood pressure. It was, however, found to have the added effect of enhanced erectile response. Let's take a look at this compound and how it works.
PDE5 is an enzyme present in various tissues of research subjects and is responsible for the contraction of various smooth muscle tissues. This tissue is found extensively in the cardiovascular system and regulates arterial constriction and dilation. This was V's initial intended research purpose; to inhibit PDE5, causing dilation in arterial blood vessels, thus reducing blood pressure in research subjects. As research progressed however it was discovered that PDE5 was highly concentrated in the corpus cavernosum of the penis. This yielded an interesting effect.
The inhibition of PDE5 by administration of V to research subjects causes a dilation of arterial blood vessels in the corpus cavenosum. As a result of this blood flow to the penis is dramatically increased. The dilation of these arterial blood vessels in turn places pressure on a membrane in the carpus cavernosum that causes a constriction in the venous blood vessel system in the penis. Essentially this increased blood flow to the penis, combined with the decreased blood flow out of the penis, causes a markedly improved impact in erectile response to be observed in research subjects.
V truly is the patriarch of the PDE5 inhibitor family. It was the first PDE5 inhibitor to be used in our research. Its across the board effectiveness has made it one of our most popular research compounds.
Check it out >> Liquid V 30mL 25mg/mL
Refs:
*SUNY Labs 42:st-1102 - "The Male Perineum and the Penis: Penis"
*Vardi M, Nini A (2007). "Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus". Cochrane Database Syst Rev (1): CD002187. doi:10.1002/14651858.CD002187.pub3. PMID 17253475
*Pfizer, Inc. (June 6, 2005). "FDA Approves Pfizer's Revatio as Treatment for Pulmonary Arterial Hypertension". 2005 News Releases. Pfizer. Retrieved December 27, 2005
*Weiss B (1975). "Differential activation and inhibition of the multiple forms of cyclic nucleotide phosphodiesterase". Adv Cyclic Nucleotide Res 5: 195–211. PMID 165666
*Diabet Med. 1998 Oct;15(10):821-5.Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Price DE, Gingell JC, Gepi-Attee S, Wareham K, Yates P, Boolell M. SourceMorriston Hospital, Swansea, UK.PMID:9796881[PubMed - indexed for MEDLINE]
Liquid V 30mL 25mg/mL
Initially this research compound was designed for the research of hypertension, or high blood pressure. It was, however, found to have the added effect of enhanced erectile response. Let's take a look at this compound and how it works.
PDE5 is an enzyme present in various tissues of research subjects and is responsible for the contraction of various smooth muscle tissues. This tissue is found extensively in the cardiovascular system and regulates arterial constriction and dilation. This was V's initial intended research purpose; to inhibit PDE5, causing dilation in arterial blood vessels, thus reducing blood pressure in research subjects. As research progressed however it was discovered that PDE5 was highly concentrated in the corpus cavernosum of the penis. This yielded an interesting effect.
The inhibition of PDE5 by administration of V to research subjects causes a dilation of arterial blood vessels in the corpus cavenosum. As a result of this blood flow to the penis is dramatically increased. The dilation of these arterial blood vessels in turn places pressure on a membrane in the carpus cavernosum that causes a constriction in the venous blood vessel system in the penis. Essentially this increased blood flow to the penis, combined with the decreased blood flow out of the penis, causes a markedly improved impact in erectile response to be observed in research subjects.
V truly is the patriarch of the PDE5 inhibitor family. It was the first PDE5 inhibitor to be used in our research. Its across the board effectiveness has made it one of our most popular research compounds.
Check it out >> Liquid V 30mL 25mg/mL
Refs:
*SUNY Labs 42:st-1102 - "The Male Perineum and the Penis: Penis"
*Vardi M, Nini A (2007). "Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus". Cochrane Database Syst Rev (1): CD002187. doi:10.1002/14651858.CD002187.pub3. PMID 17253475
*Pfizer, Inc. (June 6, 2005). "FDA Approves Pfizer's Revatio as Treatment for Pulmonary Arterial Hypertension". 2005 News Releases. Pfizer. Retrieved December 27, 2005
*Weiss B (1975). "Differential activation and inhibition of the multiple forms of cyclic nucleotide phosphodiesterase". Adv Cyclic Nucleotide Res 5: 195–211. PMID 165666
*Diabet Med. 1998 Oct;15(10):821-5.Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Price DE, Gingell JC, Gepi-Attee S, Wareham K, Yates P, Boolell M. SourceMorriston Hospital, Swansea, UK.PMID:9796881[PubMed - indexed for MEDLINE]
Liquid V 30mL 25mg/mL
